The Cancer Molecular Imaging (CMI) Program Area is comprised of 29 members, including two """"""""split"""""""" members (shared between two program areas), representing two schools and eight departments at UCLA. The NCI and other peer-reviewed cancer-related support for this Program Area is $5.7M. CMI Program Area members have produced a total number of 411 publications, of which 27% are intra-programmatic, 4 1% are inter-programmatic and 44% were in collaboration with investigators at other institutions. The main goals of the CMI Program Area are to develop new molecular imaging technologies and methodologies to provide new insights into cancer biology, to improve the diagnosis and treatment of cancer, and to translate molecular imaging approaches to the clinic. Four themes support this goal: 1) Instrumentation and analytical tools. Next-generation instrumentation provides high-resolution, sensitive and quantitative noninvasive measurement of molecular biomarkers in vivo at low cost, and facilitates adoption of novel tracers in preclinical and clinical imaging centers. 2) Novel molecular Imaging approaches. CMI members develop novel, translatable PET tracers and reporter gene systems. These probes are employed preclinically to study cancer initiation, progression and metastasis, and to predict and monitor treatment response, laying the groundwork for ciinicai translation. 3) Imaging immune responses. Immune regulation plays a key role in the development and control of cancer, as evidenced by new developments in immunotherapeutics. The CMI Program Area is developing a range of probes for imaging immune responses and monitoring cancer immunotherapy in preclinical models and patients. 4) Translational molecular imaging. CMI investigators are advancing clinical molecular imaging of cancer through first-in-human studies of new radiotracers for deoxycytidine kinase activity (dCK), engineered immunoPET probes for imaging of cell surface markers, novel reporter systems for human use, and finally, new applications of current clinical molecular tracers and modalities (e.g., FDG, FLT, as well as MRI/MRSI to investigate metabolism in gliomas and prostate cancer) to improve patient outcomes.
Cancer molecular imaging allows us to visualize the specific alterations that have occurred in cancerous tissues, in preclinical models, and, importantly, in patients. As more and more targeted therapeutics are brought forward, diagnostic tools, including molecular imaging, are becoming critical to understanding cancer biology in specific individuals, and in selecting and monitoring the most appropriate targeted drugs. The CMI Program Area ensures that the next generation of imaging tools will be available to meet these needs.
|Law, Ivy Ka Man; Jensen, Dane; Bunnett, Nigel W et al. (2016) Neurotensin-induced miR-133Î± expression regulates neurotensin receptor 1 recycling through its downstream target aftiphilin. Sci Rep 6:22195|
|Young, Courtney S; Hicks, Michael R; Ermolova, Natalia V et al. (2016) A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell 18:533-40|
|Palanichamy, Jayanth Kumar; Tran, Tiffany M; Howard, Jonathan M et al. (2016) RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. J Clin Invest 126:1495-511|
|Van Dyk, Kathleen; Ganz, Patricia A; Ercoli, Linda et al. (2016) Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient's assessment of own functioning inventory. Support Care Cancer 24:4939-4949|
|Bostean, Georgiana; Crespi, Catherine M; Vorapharuek, Patsornkarn et al. (2016) E-cigarette use among students and e-cigarette specialty retailer presence near schools. Health Place 42:129-136|
|Aguilera-Sandoval, Christian R; Yang, Otto O; Jojic, Nebojsa et al. (2016) Supranormal thymic output up to 2 decades after HIV-1 infection. AIDS 30:701-11|
|Bauer, Margaret R; Harris, Lauren N; Wiley, Joshua F et al. (2016) Dispositional and Situational Avoidance and Approach as Predictors of Physical Symptom Bother Following Breast Cancer Diagnosis. Ann Behav Med 50:370-84|
|Horvath, Steve; Gurven, Michael; Levine, Morgan E et al. (2016) An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. Genome Biol 17:171|
|Ganz, Patricia A; Petersen, Laura; Bower, Julienne E et al. (2016) Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. J Clin Oncol 34:816-24|
|Dooley, Larissa N; Ganz, Patricia A; Cole, Steve W et al. (2016) Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. J Affect Disord 197:43-50|
Showing the most recent 10 out of 568 publications